COMP <GO>
DYN vs NRIX // FORWARD P/E MULTIPLE
Dyne Therapeutics Inc. (NASDAQ) VS. Nurix Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: DYN 1
— NRIX 3
■ METRIC PARITY
LAST: $17.04 (+0.35%) • MKT CAP: $3.18B
forward-pe
—
LAST: $27.12 (-0.51%) • MKT CAP: $2.96B
forward-pe
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DYN VS. NRIX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DYN | NRIX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -12.73% | -8.89% | -3.84 | NRIX | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 54.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 9.52 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 3/9 | -2.00 | NRIX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.0 | 63.8 | -13.86 | NRIX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.18B | $2.96B | $219.3M | DYN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DYN REV | NRIX REV | DYN GROSS % | NRIX GROSS % | DYN FCF | NRIX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $84.0M | — | — | -$405.1M | -$263.5M |
| FY 2024 | $0 | $54.5M | — | — | -$294.7M | -$181.9M |
| FY 2023 | $0 | $77.0M | — | — | -$188.2M | -$81.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DYN // BETA —
NRIX // BETA —